Targeting netrin‐3 in small cell lung cancer and neuroblastoma

Archive ouverte

Jiang, Shan | Richaud, Mathieu | Vieugué, Pauline | Rama, Nicolas | Delcros, Jean‐guy | Siouda, Maha | Sanada, Mitsuaki | Redavid, Anna‐rita | Ducarouge, Benjamin | Hervieu, Maëva | Breusa, Silvia | Manceau, Ambroise | Gattolliat, Charles‐henry | Gadot, Nicolas | Combaret, Valérie | Neves, David | Ortiz-Cuaran, Sandra | Saintigny, Pierre | Meurette, Olivier | Walter, Thomas | Janoueix‐lerosey, Isabelle | Hofman, Paul | Mulligan, Peter | Goldshneider, David | Mehlen, Patrick | Gibert, Benjamin

Edité par CCSD ; Wiley Open Access -

International audience. The navigation cue netrin-1 is well-documented for its key role in cancer development and represents a promising therapeutic target currently under clinical investigation. Phase 1 and 2 clinical trials are ongoing with NP137, a humanized monoclonal antibody against netrin-1. Interestingly, the epitope recognized by NP137 in netrin-1 shares 90% homology with its counterpart in netrin-3, the closest member to netrin-1 in humans, for which little is known in the field of cancer. Here, we unveiled that netrin-3 appears to be expressed specifically in human neuroblastoma (NB) and small cell lung cancer (SCLC), two subtypes of neuroectodermal/neuroendocrine lineages. Netrin-3 and netrin-1 expression are mutually exclusive, and the former is driven by the MYCN oncogene in NB, and the ASCL-1 or NeuroD1 trThe navigation cue netrin-1 is well-documented for its key role in cancer development and represents a promising therapeutic target currently under clinical investigation. Phase 1 and 2 clinical trials are ongoing with NP137, a humanized monoclonal antibody against netrin-1. Interestingly, the epitope recognized by NP137 in netrin-1 shares 90% homology with its counterpart in netrin-3, the closest member to netrin-1 in humans, for which little is known in the field of cancer. Here, we unveiled that netrin-3 appears to be expressed specifically in human neuroblastoma (NB) and small cell lung cancer (SCLC), two subtypes of neuroectodermal/neuroendocrine lineages. Netrin-3 and netrin-1 expression are mutually exclusive, and the former is driven by the MYCN oncogene in NB, and the ASCL-1 or NeuroD1 transcription factors in SCLC. Netrin-3 expression is correlated with disease stage, aggressiveness, and overall survival in NB. Mechanistically, we confirmed the high affinity of netrin-3 for netrin-1 receptors and we demonstrated that netrin-3 genetic silencing or interference using NP137, delayed tumor engraftment, and reduced tumor growth in animal models. Altogether, these data support the targeting of netrin-3 in NB and SCLC. anscription factors in SCLC. Netrin-3 expression is correlated with disease stage, aggressiveness, and overall survival in NB. Mechanistically, we confirmed the high affinity of netrin-3 for netrin-1 receptors and we demonstrated that netrin-3 genetic silencing or interference using NP137, delayed tumor engraftment, and reduced tumor growth in animal models. Altogether, these data support the targeting of netrin-3 in NB and SCLC.

Suggestions

Du même auteur

Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor

Archive ouverte | Ducarouge, Benjamin | CCSD

International audience

From netrin‐1‐targeted SPECT / CT to internal radiotherapy for management of advanced solid tumors

Archive ouverte | Kryza, David | CCSD

International audience. Targeted radionuclide therapy is a revolutionary tool for the treatment of highly spread metastatic cancers. Most current approaches rely on the use of vectors to deliver radionuclides to tum...

Comprehensive molecular portrait reveals genetic diversity and distinct molecular subtypes of small intestinal neuroendocrine tumors

Archive ouverte | Patte, Céline | CCSD

International audience

Chargement des enrichissements...